Amgen Inc (NASDAQ:AMGN)

186.67
Delayed Data
As of Feb 23
 +4.22 / +2.31%
Today’s Change
152.16
Today|||52-Week Range
201.23
+7.34%
Year-to-Date
Ligand (LGND) Q4 Earnings & Revenues Top, 2018 View Solid
Feb 22 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Feb 16 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Feb 21 / Zacks.com - Paid Partner Content
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
Feb 16 / Zacks.com - Paid Partner Content
Top Analyst Report for Amgen, TOTAL S.A. & Marriott
Feb 20 / Zacks.com - Paid Partner Content
Roche's Rituxan Gets Priority Review for Label Expansion
Feb 14 / Zacks.com - Paid Partner Content
Minority Report
Feb 20 / GuruFocus News - Paid Partner Content
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
Feb 14 / Zacks.com - Paid Partner Content
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
Feb 20 / Zacks.com - Paid Partner Content
3 ETFs to Watch on Biotech Earnings
Feb 10 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close182.45
Today’s open183.63
Day’s range182.77 - 186.79
Volume4,163,363
Average volume (3 months)3,278,068
Market cap$134.5B
Data as of 4:00pm ET, 02/23/2018

Growth & Valuation

Earnings growth (last year)-73.73%
Earnings growth (this year)+6.48%
Earnings growth (next 5 years)+4.98%
Revenue growth (last year)+0.45%
P/E ratio69.4
Price/Sales5.61
Price/Book5.34

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+1.51+1.90%
BIIBBiogen+7.97+2.80%
ILMNIllumina Inc+7.10+3.13%
----
Data as of 4:00pm ET, 02/23/2018

Financials

Next reporting dateApril 24, 2018
EPS forecast (this quarter)$3.03
Annual revenue (last year)$22.8B
Annual profit (last year)$2.0B
Net profit margin8.69%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts